BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zactima vandetanib: Phase II data

In the double-blind Phase II ZACTHYF trial in 145 patients who failed treatment with or were unsuitable for treatment with radioiodine therapy, once-daily 300 mg oral Zactima met the primary endpoint of significantly improving PFS vs. placebo (11 vs. 5.8 months, p=0.008). Zactima missed the secondary endpoints of significantly improving ORR (8.3% vs. 5.5%) and DCR at 6 months (56.9% vs. 42.5%) vs....

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >